Therapeutic Asset Ratings

9,922 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Kb-Gdt-01 Metastatic Carcinoma In The Bone	Kiromic BioPharma Inc.	P1	CC (43)
Kb-Gdt-01 Non-Small Cell Lung Carcinoma	Kiromic BioPharma Inc.	P1	CC (43)
kfa115 Ovarian Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
kfa115 Renal Cell Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
kfa115 Thymic Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
kfa115 Gastroesophageal Cancer	Novartis Pharmaceuticals	P1	CC (43)
kfa115 Triple-Negative Breast Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
Kin-3248 Intrahepatic Cholangiocarcinoma	Kinnate Biopharma	P1	CC (43)
Kite-197 Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Kite, A Gilead Company	P1	CC (43)
Kite-363 Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Kite, A Gilead Company	P1	CC (43)
Kite-363 Myasthenia Gravis	Kite, A Gilead Company	P1	CC (43)
kj015 Bile Duct Cancer	Shanghai Bao Pharmaceuticals Co., Ltd.	P1	CC (43)
kj015 Gastroesophageal Cancer	Shanghai Bao Pharmaceuticals Co., Ltd.	P1	CC (43)
kk2845_1 Acute Myeloid Leukemia	Kyowa Kirin Co., Ltd.	P1	CC (43)
kk2845_2 Acute Myeloid Leukemia	Kyowa Kirin Co., Ltd.	P1	CC (43)
kk2845_3 Acute Myeloid Leukemia	Kyowa Kirin Co., Ltd.	P1	CC (43)
kk2845_4 Acute Myeloid Leukemia	Kyowa Kirin Co., Ltd.	P1	CC (43)
kk2845_5 Acute Myeloid Leukemia	Kyowa Kirin Co., Ltd.	P1	CC (43)
kk2845_6 Acute Myeloid Leukemia	Kyowa Kirin Co., Ltd.	P1	CC (43)
Kln-1010 Hematologic Disorder	Kelonia Therapeutics, Inc.	P1	CC (43)
Kln-1010 Vascular Hemostatic Disease	Kelonia Therapeutics, Inc.	P1	CC (43)
Kln-1010 Immune System Disorder	Kelonia Therapeutics, Inc.	P1	CC (43)
Kln-1010 Immunoproliferative Disorder	Kelonia Therapeutics, Inc.	P1	CC (43)
Kln-1010 Lymphoproliferative Syndrome	Kelonia Therapeutics, Inc.	P1	CC (43)
Kln-1010 Plasma Cell Myeloma	Kelonia Therapeutics, Inc.	P1	CC (43)

Showing 2601 to 2625 of 9,922 assets

PreviousPage 105 of 397Next